AHCC (Active Hexose Correlated Compound) and HPV

What 3 graded rows on ahcc (active hexose correlated compound) agree on for HPV, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the AHCC (Active Hexose Correlated Compound) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the AHCC (Active Hexose Correlated Compound) page, with its PubMed record.

Supplement

AHCC (Active Hexose Correlated Compound) Choose another

3 rows · 203 people

Mostly an improvement: 2 of 3 rows, and most of the people. 1 had mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade C, is a randomized trial of 50 people (2022) and found an improvement.

The rows run from 20 to 133 people, published from 2019 to 2025: 3 single studies.

2 improved · 1 mixed

Grade CClearance of persistent high-risk HPV · Improved
RCT · n 50 · 2022 · 50 women over 30 with high-risk HPV for more than 2 years; 41 completed
3 g once daily on an empty stomach · 6 months, then 6 months off
14 of 22 (63.6%) on AHCC were HPV RNA/DNA negative after 6 months, and 64.3% of them stayed negative 6 months later; 2 of 19 (10.5%) on placebo were negative at 12 months.
Row on the AHCC (Active Hexose Correlated Compound) page · PubMed 35814366 (opens PubMed)
Grade DHPV clearance in two pilot studies · Improved
Open-label trial · n 20 · 2019 · Two pilot studies of 10 women each with persistent high-risk HPV
3 g or 1 g a day · Up to 8 months
4 of 6 (66.7%) cleared HPV after 3-6 months of 3 g, and 4 of 9 (44%) after 7 months of 1 g.
Row on the AHCC (Active Hexose Correlated Compound) page · PubMed 30949451 (opens PubMed)
Grade DWart recurrence after cauterisation of genital warts · Mixed
Observational · n 133 · 2025 · 133 patients treated for genital warts (condyloma acuminata), reviewed retrospectively
Dose not stated in the abstract · Follow-up every 3 months
Among patients whose warts returned, AHCC users had fewer (p = 0.019) and smaller (p = 0.042) warts; the authors say AHCC is not expected to stop recurrence in all patients.
Row on the AHCC (Active Hexose Correlated Compound) page · PubMed 40282913 (opens PubMed)